MG
MRSN

Michael Gelband’s Mersana Therapeutics MRSN Stock Holding History

Michael Gelband’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-457
Closed -$3K – 1849
2025
Q2 		$3K Buy
+457
New +$4.02K ﹤0.01% 1404
2025
Q1 		– Sell
-7,766
Closed -$278K – 1802
2024
Q4 		$278K Buy
+7,766
New +$402K ﹤0.01% 1298
2024
Q3 		– Sell
-4,287
Closed -$215K – 1916
2024
Q2 		$215K Buy
+4,287
New +$310K ﹤0.01% 1384
2023
Q2 		– Sell
-1,601
Closed -$165K – 2111
2023
Q1 		$165K Buy
1,601
+1,129
+239% +$158K ﹤0.01% 1595
2022
Q4 		$69K Sell
472
-5,824
-93% -$984K ﹤0.01% 1535
2022
Q3 		$1.06M Buy
6,296
+5,275
+517% +$857K 0.01% 1083
2022
Q2 		$118K Sell
1,021
-10,063
-91% -$946K ﹤0.01% 1729
2022
Q1 		$1.11M Buy
11,084
+9,868
+812% +$1.15M 0.01% 1086
2021
Q4 		$189K Buy
+1,216
New +$237K ﹤0.01% 1843
2021
Q3 		– Sell
-846
Closed -$287K – 2445
2021
Q2 		$287K Buy
+846
New +$320K ﹤0.01% 1770
2021
Q1 		– Sell
-1,308
Closed -$870K – 2419
2020
Q4 		$870K Sell
1,308
-490
-27% -$272K 0.01% 933
2020
Q3 		$837K Buy
+1,798
New +$908K 0.02% 764
2019
Q2 		– Sell
-2,180
Closed -$287K – 1257
2019
Q1 		$287K Buy
+2,180
New +$274K 0.02% 478

Other funds holding MRSN

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
AV
Alamea Verwaltungs Edison, New Jersey $125M AUM 27.56% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Michael Gelband's MRSN Position: Q3 2025 in Review

Michael Gelband sold out of Mersana Therapeutics (MRSN) in Q3 2025, closing a stake of 457 shares — an estimated $3K sold.

Michael Gelband first reported a position in MRSN in Q1 2019 and held it in 13 quarters. The position peaked at $1.11M in Q1 2022. 49 funds tracked by Wall St. Rank hold MRSN as of Q3 2025.

  • Michael Gelband reported no remaining Mersana Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Michael Gelband sold 457 Mersana Therapeutics shares in Q3 2025, an estimated $3K.
  • Michael Gelband first reported a position in Mersana Therapeutics in Q1 2019 and held it in 13 quarters.
  • Michael Gelband's Mersana Therapeutics position peaked at $1.11M in Q1 2022.
  • 49 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q3 2025.

Based on ExodusPoint Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.